Loading
Polypharmacy / Alzheimer's Disease and Related Dementias / Pharmacist-led deprescribing intervention · Interventional Study
ClinicalTrials.gov · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed interventional trial of a pharmacist-led deprescribing intervention for people with dementia and their care partners, registered at ClinicalTrials.gov with planned enrollment of 474 participants. No efficacy, safety, or outcome data are reported in this registry record; results have not yet been posted.
Interventional, Randomized, Parallel, Open label, Health Services Research purpose. Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment; age from 65 Years; accepts healthy volunteers. Intervention: Intervention. Compared with: Delayed intervention (wait list control) — Active Comparator. n = 474. 1 site: United States.
This is a completed interventional trial of a pharmacist-led deprescribing intervention for people with dementia and their care partners, registered at ClinicalTrials.gov with planned enrollment of 474 participants. No efficacy, safety, or outcome data are reported in this registry record; results have not yet been posted.
No efficacy, safety, or outcome data reported in this registry record.
Results from this trial, when published, could inform the adoption of pharmacist-led deprescribing interventions in primary care for dementia populations. Clinicians should await full peer-reviewed publication of outcomes before clinical implementation.
This is a completed trial registration with no results posted; the study design and planned outcomes are documented but effectiveness data are not reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Results from this trial, when published, could inform the adoption of pharmacist-led deprescribing interventions in primary care for dementia populations. Clinicians should await full peer-reviewed publication of outcomes before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06335953). This is a study registration, not published results. Lead sponsor: Johns Hopkins University. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 474 participants (ACTUAL). Conditions: Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment. Interventions: BEHAVIORAL: Pharmacist-led deprescribing intervention. Primary outcome measures: Patients Who Stop One or More Medications - Per Protocol , 3 months; Patients Who Stop One or More Medications - Intention-to-Treat , 3 months. Brief summary: The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners. The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and care partner in the context of the person's goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored de-prescribing recommendations designed to be useful and actionable for the PCP. The investigators will compare the intervention group with the waitlist control group to see if there is a difference in the primary outcome, the proportion of patients who deprescribe at least one medication by 3 months.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.